Description: We are a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of our platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. We are leveraging our unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next generation sample (NGS) preparation, and antibody libraries for drug discovery and development. We are also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. We make products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Home Page: www.twistbioscience.com
TWST Technical Analysis
681 Gateway Boulevard
South San Francisco,
CA
94080
United States
Phone:
800 719 0671
Officers
| Name | Title |
|---|---|
| Dr. Emily Marine Leproust Ph.D. | Co-Founder, Chairman & CEO |
| Dr. Patrick John Finn Ph.D. | Pres & COO |
| Mr. James M. Thorburn | Chief Financial Officer |
| Dr. William Charles Banyai Ph.D. | Sr. VP of Advanced Devel., GM of Data Storage & Director |
| Mr. Kevin B. Yankton | VP & Chief Accounting Officer |
| Mr. Siyuan Chen | Chief Technology Officer |
| Dr. Aaron K. Sato Ph.D. | Chief Scientific Officer |
| Mr. Dennis Cho | Sr. VP, Gen. Counsel, Chief Ethics & Compliance Officer |
| Ms. Paula Green | Sr. VP of HR |
| Ms. Erin Smith | Sr. VP of Gov. Affairs & Public Policy |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.8983 |
| Price-to-Sales TTM: | 7.0528 |
| IPO Date: | 2018-10-31 |
| Fiscal Year End: | September |
| Full Time Employees: | 989 |